GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
GH Research PLC (Nasdaq: GHRS) has announced a conference call and webcast scheduled for February 3, 2025, at 8:00 a.m. EST. The purpose is to provide updates on data from their Phase 2b trial of GH001 in treatment-resistant depression (TRD). The trial is characterized as randomized, double-blind, and placebo-controlled. The event will be accessible through advance registration and will be available on the company's website under the Events & Presentations section.
GH Research PLC (Nasdaq: GHRS) ha annunciato una conference call e un webcast programmati per il 3 febbraio 2025, alle 8:00 EST. Lo scopo è fornire aggiornamenti sui dati del loro trial di Fase 2b di GH001 nel trattamento della depressione resistente (TRD). Il trial è caratterizzato come randomizzato, in doppio cieco e controllato con placebo. L'evento sarà accessibile previa registrazione e sarà disponibile sul sito web dell'azienda nella sezione Eventi e Presentazioni.
GH Research PLC (Nasdaq: GHRS) ha anunciado una conferencia telefónica y un webcast programados para el 3 de febrero de 2025, a las 8:00 a.m. EST. El propósito es proporcionar actualizaciones sobre los datos de su ensayo de Fase 2b de GH001 en depresión resistente al tratamiento (TRD). El ensayo se caracteriza por ser aleatorio, doble ciego y controlado por placebo. El evento será accesible mediante registro previo y estará disponible en el sitio web de la compañía en la sección de Eventos y Presentaciones.
GH Research PLC (Nasdaq: GHRS)는 2025년 2월 3일 오전 8시 EST에 예정된 컨퍼런스 콜과 웹캐스트를 발표했습니다. 이 목적은 TRD(치료 내성 우울증)에 대한 GH001의 2b상 시험 데이터 업데이트를 제공하는 것입니다. 이 시험은 무작위 배정, 이중 맹검 및 플라시보 대조로 이루어집니다. 이 이벤트는 사전 등록을 통해 접근 가능하며, 회사 웹사이트의 이벤트 및 발표 섹션에서 확인할 수 있습니다.
GH Research PLC (Nasdaq: GHRS) a annoncé une conférence téléphonique et un webcast programmés pour le 3 février 2025, à 8h00 EST. L'objectif est de fournir des mises à jour sur les données de leur essai de Phase 2b de GH001 dans le cadre de la dépression résistante au traitement (TRD). L'essai est caractérisé comme randomisé, en double aveugle et contrôlé par placebo. L'événement sera accessible sur inscription préalable et sera disponible sur le site Web de l'entreprise dans la section Événements et Présentations.
GH Research PLC (Nasdaq: GHRS) hat eine Telefonkonferenz und einen Webcast angekündigt, die am 3. Februar 2025 um 8:00 Uhr EST stattfinden. Ziel ist es, Updates zu den Daten ihrer Phase 2b Studie zu GH001 bei therapieresistenter Depression (TRD) bereitzustellen. Die Studie ist als randomisiert, doppelblinded und placebo-kontrolliert charakterisiert. Die Veranstaltung wird nach vorheriger Anmeldung zugänglich sein und auf der Website des Unternehmens im Bereich Veranstaltungen & Präsentationen verfügbar sein.
- None.
- None.
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).
To access the conference call, please register in advance here. A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where
Investor Relations
Julie Ryan
GH Research PLC
investors@ghres.com
FAQ
When will GH Research (GHRS) announce its Phase 2b trial results for GH001?
What type of clinical trial is GHRS conducting for GH001?
How can investors access GHRS's Phase 2b trial update webcast?
What indication is GH Research (GHRS) targeting with GH001?
